<article xmlns:ns0="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0220671</article-id>
<article-id pub-id-type="publisher-id">PONE-D-19-15391</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Gut bacteria</subject><subj-group><subject>Clostridium difficile</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Biofilms</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject><subj-group><subject>Vancomycin</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject><subj-group><subject>Vancomycin</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Bacteriology</subject><subj-group><subject>Bacterial physiology</subject><subj-group><subject>Bacterial sporulation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial physiology</subject><subj-group><subject>Bacterial physiology</subject><subj-group><subject>Bacterial sporulation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Bacteriology</subject><subj-group><subject>Bacterial biofilms</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Biofilms</subject><subj-group><subject>Bacterial biofilms</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial control</subject><subj-group><subject>Antimicrobial resistance</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Antimicrobial resistance</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Biological cultures</subject><subj-group><subject>Cell culturing techniques</subject><subj-group><subject>Biofilm culture</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent <italic>Clostridium</italic> [<italic>Clostridioides</italic>] <italic>difficile</italic> infection isolates</article-title>
<alt-title alt-title-type="running-head">Sporulation and overexpression of virulence factors in biofilms and reduced susceptibility in R-CDI</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Tijerina-Rodr&#237;guez</surname>
<given-names>Laura</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; original draft</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Villarreal-Trevi&#241;o</surname>
<given-names>Licet</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Baines</surname>
<given-names>Simon D.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Morf&#237;n-Otero</surname>
<given-names>Rayo</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Camacho-Ort&#237;z</surname>
<given-names>Adri&#225;n</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Flores-Trevi&#241;o</surname>
<given-names>Samantha</given-names>
</name>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Maldonado-Garza</surname>
<given-names>H&#233;ctor</given-names>
</name>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Rodr&#237;guez-Noriega</surname>
<given-names>Eduardo</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" ns0:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5831-9661</contrib-id>
<name name-style="western">
<surname>Garza-Gonz&#225;lez</surname>
<given-names>Elvira</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; original draft</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Departamento de Microbiolog&#237;a e Inmunolog&#237;a, Facultad de Ciencias Biol&#243;gicas, Universidad Aut&#243;noma de Nuevo Le&#243;n, San Nicol&#225;s de los Garza, Mexico</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Biological and Environmental Sciences, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Instituto de Patolog&#237;a Infecciosa y Experimental, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Hospital Civil de Guadalajara &#8220;Fray Antonio Alcalde&#8221;, Guadalajara, Mexico</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Hospital Universitario &#8220;Dr. Jos&#233; Eleuterio Gonz&#225;lez&#8221;, Universidad Aut&#243;noma de Nuevo Le&#243;n, Monterrey, Mexico</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" ns0:type="simple">
<name name-style="western">
<surname>Chang</surname>
<given-names>Yung-Fu</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1" />
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Cornell University, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email ns0:type="simple">elvira_garza_gzz@yahoo.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>31</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>14</volume>
<issue>7</issue>
<elocation-id>e0220671</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>5</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>7</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Tijerina-Rodr&#237;guez et al</copyright-holder>
<license ns0:href="http://creativecommons.org/licenses/by/4.0/" ns0:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" ns0:href="http://creativecommons.org/licenses/by/4.0/" ns0:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" ns0:href="info:doi/10.1371/journal.pone.0220671" />
<abstract>
<p><italic>Clostridium</italic> [<italic>Clostridioides</italic>] <italic>difficile</italic> infection (CDI) is one of the leading causes of diarrhea associated with medical care worldwide, and up to 60% of patients with CDI can develop a recurrent infection (R-CDI). A multi-species microbiota biofilm model of <italic>C</italic>. <italic>difficile</italic> was designed to evaluate the differences in the production of biofilms, sporulation, susceptibility to drugs, expression of sporulating (<italic>sigH</italic>, <italic>spo0A)</italic>, quorum sensing (<italic>agrD</italic><sub><italic>1</italic></sub>, and <italic>luxS)</italic>, and adhesion-associated (<italic>slpA</italic> and <italic>cwp84)</italic> pathway genes between selected <italic>C</italic>. <italic>difficile</italic> isolates from R-CDI and non-recurrent patients (NR-CDI). We obtained 102 <italic>C</italic>. <italic>difficile</italic> isolates from 254 patients with confirmed CDI (66 from NR-CDI and 36 from R-CDI). Most of the isolates were biofilm producers, and most of the strains were ribotype 027 (81.374%, 83/102). Most <italic>C</italic>. <italic>difficile</italic> isolates were producers of biofilm (100/102), and most were strongly adherent. Sporulation was higher in the R-CDI than in the NR-CDI isolates (p = 0.015). The isolates from R-CDI patients more frequently demonstrated reduced susceptibility to vancomycin than isolates of NR-CDI patients (27.78% [10/36] and 9.09% [6/66], respectively, p = 0.013). The minimum inhibitory concentrations for vancomycin and linezolid against biofilms (BMIC) were up to 100 times and 20 times higher, respectively, than the corresponding planktonic MICs. Expression of <italic>sigH</italic>, <italic>spo0A</italic>, <italic>cwp84</italic>, and <italic>agrD</italic><sub><italic>1</italic></sub> was higher in R-CDI than in NR-CDI isolates. Most of the <italic>C</italic>. <italic>difficile</italic> isolates were producers of biofilms with no correlation with the ribotype. Sporulation was greater in R-CDI than in NR-CDI isolates in the biofilm model of <italic>C</italic>. <italic>difficile</italic>. The R-CDI isolates more frequently demonstrated reduced susceptibility to vancomycin and linezolid than the NR-CDI isolates in both planktonic cells and biofilm isolates. A higher expression of sporulating pathway (<italic>sigH</italic>, <italic>spo0A</italic>), quorum sensing (<italic>agrD</italic><sub><italic>1</italic></sub>), and adhesion-associated (<italic>cwp84</italic>) genes was found in R-CDI than in NR-CDI isolates. All of these factors can have effect on the recurrence of the infection.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003141</institution-id>
<institution>Consejo Nacional de Ciencia y Tecnolog&#237;a</institution>
</institution-wrap>
</funding-source>
<award-id>284042</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Tijerina-Rodr&#237;guez</surname>
<given-names>Laura</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This work was partially supported by Mexico&#8217;s National Council for Science and Technology, CONACYT, grant 284042. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="1" />
<table-count count="5" />
<page-count count="14" />
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p><italic>Clostridium</italic> [<italic>Clostridioides</italic>] <italic>difficile</italic> is one of the leading causes of healthcare-associated diarrhea worldwide. Since 2011, cases of <italic>C</italic>. <italic>difficile</italic> infection (CDI) have increased in the United States, with 453,000 infections and 29,000 deaths [<xref ref-type="bibr" rid="pone.0220671.ref001">1</xref>].</p>
<p>An estimated 20&#8211;35% of patients with CDI can develop a recurrent infection (R-CDI) within eight weeks of the first episode, with an incidence of 1,846&#8211;37,620 cases/year [<xref ref-type="bibr" rid="pone.0220671.ref002">2</xref>]. The development of R-CDI has been associated with the germination of spores of the strain that produced the initial infection in the colon or with the acquisition of a new strain [<xref ref-type="bibr" rid="pone.0220671.ref003">3</xref>&#8211;<xref ref-type="bibr" rid="pone.0220671.ref005">5</xref>].</p>
<p>The pathogenicity of chronic and recurrent infections has been associated with the production of biofilm in some bacterial species [<xref ref-type="bibr" rid="pone.0220671.ref006">6</xref>], and <italic>C</italic>. <italic>difficile</italic> has been shown to produce organized biofilm communities on abiotic surfaces <italic>in vitro</italic> [<xref ref-type="bibr" rid="pone.0220671.ref007">7</xref>&#8211;<xref ref-type="bibr" rid="pone.0220671.ref009">9</xref>]. Furthermore, <italic>C</italic>. <italic>difficile</italic> has shown to produce biofilms in the presence of other bacteria such as <italic>Finegoldia magna in vitro</italic> and participate in complex gut microbiota biofilms <italic>in vitro</italic> and during infection <italic>in vivo</italic> in a mouse model [<xref ref-type="bibr" rid="pone.0220671.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0220671.ref011">11</xref>]. Such biofilm formation could protect bacteria from cellular immune responses associated with toxin production and from antibiotics used for the treatment of CDI [<xref ref-type="bibr" rid="pone.0220671.ref010">10</xref>].</p>
<p><italic>C</italic>. <italic>difficile</italic> spores have been found within the biofilms in a simulated chemostat gut model [<xref ref-type="bibr" rid="pone.0220671.ref011">11</xref>, <xref ref-type="bibr" rid="pone.0220671.ref012">12</xref>], suggesting that the accumulation of spores within the biofilm of <italic>C</italic>. <italic>difficile</italic> could play a role in the development of R-CDI [<xref ref-type="bibr" rid="pone.0220671.ref013">13</xref>]. Lower spore germination rates have been reported in <italic>C</italic>. <italic>difficile</italic> biofilms than in vegetative cultures [<xref ref-type="bibr" rid="pone.0220671.ref014">14</xref>, <xref ref-type="bibr" rid="pone.0220671.ref015">15</xref>], which may affect the persistence of infection.</p>
<p>The development of biofilms has been associated with the ability of bacteria to resist antimicrobial agents because they act as a physical barrier and decrease the effective concentration of antimicrobials [<xref ref-type="bibr" rid="pone.0220671.ref008">8</xref>, <xref ref-type="bibr" rid="pone.0220671.ref010">10</xref>]. Indeed, the biofilms of <italic>C</italic>. <italic>difficile</italic> have shown 100 times greater resistance to metronidazole and 10 times greater resistance to vancomycin than cells cultured in liquid media [<xref ref-type="bibr" rid="pone.0220671.ref014">14</xref>].</p>
<p>Several factors have been described to have a key role in the formation of <italic>C</italic>. <italic>difficile</italic> biofilm, such as surface factors like S-layer protein, SlpA (encoded by <italic>slpA</italic>), the cell wall protein Cwp84 (encoded by <italic>cwp84</italic>), and the putative quorum sensing regulator LuxS (encoded by <italic>luxS</italic>) [<xref ref-type="bibr" rid="pone.0220671.ref008">8</xref>, <xref ref-type="bibr" rid="pone.0220671.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0220671.ref016">16</xref>]. In addition, the master regulator of sporulation, Spo0A, has shown to determine the biofilm-producing phenotype [<xref ref-type="bibr" rid="pone.0220671.ref007">7</xref>, <xref ref-type="bibr" rid="pone.0220671.ref014">14</xref>]. Recently, the sigma factor of sporulation, SigH, and the <italic>agr</italic> quorum sensing system, have been shown to regulate metabolism and virulence potential in <italic>C</italic>. <italic>difficile</italic> [<xref ref-type="bibr" rid="pone.0220671.ref017">17</xref>&#8211;<xref ref-type="bibr" rid="pone.0220671.ref020">20</xref>]. Nevertheless, their contributory role in R-CDI development remains unknown.</p>
<p>Therefore, the aim of this study was to evaluate the effect of biofilm production in a range of <italic>C</italic>. <italic>difficile</italic> ribotypes, their sporulation, antimicrobial susceptibilities, and expression of genes involved in sporulation and biofilm formation in isolates from recurrent and non-recurrent CDI patients.</p>
</sec>
<sec id="sec002">
<title>Material and methods</title>
<sec id="sec003">
<title>Setting</title>
<p>Patients were recruited for this study who were treated at the following two hospitals in Mexico: The Civil Hospital of Guadalajara, "Fray Antonio Alcalde" a tertiary hospital with 1000 beds in Guadalajara; and the University Hospital "Dr. Jos&#233; Eleuterio Gonz&#225;lez," a tertiary teaching hospital with 500 beds in Monterrey.</p>
</sec>
<sec id="sec004">
<title>Ethics statement</title>
<p>The local ethics committee (Comit&#233; de &#201;tica en Investigaci&#243;n del Antiguo Hospital Civil de Guadalajara &#8220;Fray Antonio Alcalde,&#8221; Jalisco, Mexico) approved this study with reference number 047/16. Informed consent was waived by the Ethics Committee because no intervention was involved and no patients identifying information was included.</p>
</sec>
<sec id="sec005">
<title>Study population, CDI diagnosis, and classification of CDI</title>
<p>Patients with unexplained diarrhea (&#8805; 3 unformed stools, Bristol scale 5&#8211;7) within 24 h were included. For the diagnosis of CDI, fecal samples were collected, and <italic>C</italic>. <italic>difficile</italic> was investigated by real-time PCR (Cepheid Xpert <italic>C</italic>. <italic>difficile</italic>/Epi test, Cepheid, Sunnyvale CA). Patients were defined with CDI when patients were diarrheal and PCR was positive.</p>
<p>R-CDI was defined by the reappearance of diarrhea associated with CDI within eight weeks after the completion of antibiotic therapy or the resolution of the initial episode [<xref ref-type="bibr" rid="pone.0220671.ref021">21</xref>]. CDI was classified as NR-CDI when no new episode occurred within eight weeks. Data collected from patients with R-CDI and NR-CDI included epidemiological and clinical data, prior antibiotic therapy, and treatment for CDI. The study was reviewed and approved by the Local Ethics Committee (Approval: 047/16).</p>
</sec>
<sec id="sec006">
<title>Culture of <italic>C</italic>. <italic>difficile</italic> and typing of isolates</title>
<p>Fecal specimens were cultured on <italic>C</italic>. <italic>difficile</italic> agar (Neogen Corporation, MI) with cefoxitin (16 mg/L) and incubated in an anaerobic chamber (10% CO<sub>2</sub>, 10% H<sub>2</sub>, and 80% N<sub>2</sub>) at 37&#176;C for 48 h. Isolates were identified by polymerase chain reaction (PCR) with amplification of the triose phosphate isomerase (<italic>tpi</italic>) gene [<xref ref-type="bibr" rid="pone.0220671.ref022">22</xref>] and by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). All isolates were stored at &#8722;80&#176;C. The <italic>tcdA</italic>, <italic>tcdB</italic>, <italic>cdtA</italic>, and <italic>cdtB</italic> genes were amplified using a multiplex PCR method [<xref ref-type="bibr" rid="pone.0220671.ref022">22</xref>], and the ribotyping-PCR was performed as previously described [<xref ref-type="bibr" rid="pone.0220671.ref023">23</xref>].</p>
<p>Selected isolates were subjected to ribotyping by capillary electrophoresis at the <italic>C</italic>. <italic>difficile</italic> Ribotyping Network Reference Laboratory (CDRN) at Leeds Teaching Hospitals NHS Trust (Leeds, United Kingdom).</p>
</sec>
<sec id="sec007">
<title><italic>C</italic>. <italic>difficile</italic> biofilm model</title>
<p>The biofilm of <italic>C</italic>. <italic>difficile</italic> formation was conducted as reported previously with some modifications. [<xref ref-type="bibr" rid="pone.0220671.ref007">7</xref>, <xref ref-type="bibr" rid="pone.0220671.ref024">24</xref>] Briefly, each isolate was cultured in brain heart infusion (BHI) broth supplemented with 0.5% yeast extract and 0.1% L-cysteine (BHIS) in 96-well microtiter plates and incubated in anaerobic conditions at 37&#176;C for 7 days. The planktonic cells were removed, and absorbance of planktonic cultures was read at 590 nm using a microtiter plate spectrometer iMarK (Bio-Rad, Hercules, CA, USA). The biofilm was washed with sterile phosphate-buffered saline (PBS) (200 &#956;l), fixed with 2% glutaraldehyde, and washed again with PBS. Then, 1% crystal violet was added and the biofilm was washed six more times with sterile water and de-stained with 30% acetic acid. The optical density was read at 590 nm. The adherence index (AI) was calculated, and the isolates were classified as strong adherents (AI &gt; 1.20), moderate adherents (0.90 &lt; AI &lt;1.20), weak adherents (AI between 0.2 and 0.90) and non-adherents (AI &lt; 0.2) [<xref ref-type="bibr" rid="pone.0220671.ref025">25</xref>]. The assays were performed in triplicate, and only the results with a variation coefficient greater than 20% were accepted.</p>
</sec>
<sec id="sec008">
<title>Microbiota&#8211;<italic>C</italic>. <italic>difficile</italic> biofilm model</title>
<p>For this study, we designed a biofilm model containing <italic>C</italic>. <italic>difficile</italic> and species from the intestinal microbiota (<italic>Enterococcus faecalis</italic> ATCC 29212, <italic>E</italic>. <italic>faecium</italic>, <italic>Lactobacillus casei</italic>, <italic>Lactobacillus rahmnosus</italic>, and <italic>Lactobacillus acidophilus</italic> strains obtained from clinical specimens). Each strain was cultured in BHIS at 37&#176;C in an anaerobic chamber for 24&#8211;48 h and subsequently diluted 1:10 in BHIS broth. A 200-&#956;l mixture of microbiota and <italic>C</italic>. <italic>difficile</italic> (1:1:1:1:1:1 of each species) were added to each well of a microtiter plate, and the plates were incubated in an anaerobic chamber at 37&#176;C for 7 days. The determination of the biofilm was carried out according to the biofilm model of <italic>C</italic>. <italic>difficile</italic> only.</p>
<p>Strains ATCC BAA-1805 (ribotype 027, strong adherent) and ATCC 9689 (ribotype 001, weak adherent) were used as controls in the biofilm assays.</p>
</sec>
<sec id="sec009">
<title>Antimicrobial susceptibility testing</title>
<p>Antimicrobial susceptibilities were determined by the agar dilution method in selected isolates [<xref ref-type="bibr" rid="pone.0220671.ref026">26</xref>]. Antibiotics used to treat CDI infections, as well as those associated with the development of CDI, were included. The minimum inhibitory concentrations (MICs) were determined for metronidazole (ICN Biomedical, Costa Mesa, CA), vancomycin, linezolid, ciprofloxacin, moxifloxacin, erythromycin, clindamycin, rifampicin, and tetracycline (Sigma-Aldrich). The antimicrobial diluents used and the ranges tested were recommended by the Clinical and Laboratory Standards Institute (CLSI, 2019, M100-S28). An overnight culture in Schaedler broth (Neogen Corporation) of each isolate was inoculated using a multipoint inoculator (10<sup>4</sup> colony-forming units (CFU)/spot) on Wilkins-Chalgren agar (Neogen Corporation) [<xref ref-type="bibr" rid="pone.0220671.ref027">27</xref>]. The ATCC 700057 (ribotype 038) was used as a control strain.</p>
<p>Resistance breakpoints were defined according to the CLSI guidelines as follows: moxifloxacin and clindamycin &#8805; 8 mg/L, tetracycline &#8805; 16 mg/L, metronidazole &#8805; 32 mg/L, (CLSI, 2019). The breakpoint for vancomycin was defined according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2019) as greater than 2 mg/L. For antimicrobial agents of which no standard breakpoints to <italic>C</italic>. <italic>difficile</italic> have yet to be defined, breakpoints were considered as follows: erythromycin &#8805; 8 mg/L (CLSI, 2013), ciprofloxacin, &#8805; 8 mg/L, [<xref ref-type="bibr" rid="pone.0220671.ref028">28</xref>] linezolid &#8805; 16 mg/L [<xref ref-type="bibr" rid="pone.0220671.ref029">29</xref>], and rifampicin &#8805; 32 mg/L [<xref ref-type="bibr" rid="pone.0220671.ref030">30</xref>].</p>
</sec>
<sec id="sec010">
<title>Biofilm minimum inhibitory concentration</title>
<p>The BMIC was determined for vancomycin and linezolid. Briefly, the planktonic phase of a 7-day-old biofilm was removed, and the antibiotics were prepared in fresh BHIS. Each concentration (from 512 mg/L to 0.5 mg/L) was aliquoted into microtiter plates (one per concentration), and 200 &#956;l per well were added. The biofilm was resuspended, and the plates were incubated at 37&#176;C for 48 h in anaerobiosis.</p>
<p>The BMIC was defined as the lowest concentration of an antimicrobial that prevents growth. The ATCC 700057 <italic>C</italic>. <italic>difficile</italic> strain (ribotype 038) was used as a control.</p>
</sec>
<sec id="sec011">
<title>Spore count in the biofilm</title>
<p>The 7-day-old biofilm was disrupted with a pipette and resuspended in 100 &#956;l PBS. Serial ten-fold dilutions (10<sup>&#8722;1</sup>&#8211;10<sup>&#8722;7</sup>) were incubated at 65&#176;C for 20 min to kill the vegetative cells. Both untreated and heat-treated suspensions were streaked on <italic>Clostridium difficile</italic> agar (Neogen Corporation, MI, USA) and incubated at 37&#176;C for 48 h in anaerobic conditions. Total viable cells and spore counts were determined as CFU/biofilm.</p>
</sec>
<sec id="sec012">
<title>Quantitative RT-PCR for <italic>spo0A</italic>, <italic>sigH</italic>, <italic>slpA</italic>, <italic>cwp84</italic>, <italic>agrD</italic><sub><italic>1</italic></sub>, and <italic>luxS</italic></title>
<p>Twenty selected strains (10 from R-CDI patients and 10 from NR-CDI patients) were analyzed. The biofilms incubated for 48 h were washed twice, then the pellet was resuspended in DEPC water (200 &#956;l) and treated with lysozyme (10 mg/ml) (Bio-basic, Ontario, Canada) and proteinase K (Bio-basic). Total RNA was isolated using the Qiagen QIAamp DSP Viral RNA mini kit (QIAGEN, Hilden, Germany). The quantity and quality of the RNA were assessed using a NanoDrop spectrophotometer. The relative quantification of the expression of the RNA transcripts of the <italic>spo0A</italic>, <italic>sigH</italic>, <italic>slpA</italic>, <italic>cwp84</italic>, <italic>agrD</italic><sub><italic>1</italic></sub>, and <italic>luxS</italic> genes normalized to 16S rRNA (<italic>rrs</italic>) was analyzed using the SuperScript III Platinum One-Step kit (Invitrogen, CA, USA).</p>
<p>Standard curves were generated using 5-fold dilutions of ATCC 9689 RNA for each gene to determine the efficiency of the reactions. RNA and diethyl pyrocarbonate (DEPC) water controls were also included. The real-time RT-PCRs were performed in two biological samples in duplicate; 200 ng RNA and 0.5 &#956;l specific primers at 100 nM (listed on <xref ref-type="table" rid="pone.0220671.t001">Table 1</xref>) in a 25-&#956;L reaction volume were used. The Smart Cycler real-time PCR system (Cepheid) was used with cycling conditions as follows: 94&#176;C for 8 min, then 45 cycles of 94&#176;C for 30 s; 60&#176;C for <italic>spo0A</italic>, <italic>sigH</italic> and <italic>cwp84</italic>; 54&#176;C for <italic>slpA</italic>, <italic>agrD</italic><sub><italic>1</italic></sub> and 30 s for <italic>luxS</italic> and an extension cycle of 72&#176;C for 25 s. Melting curves were determined to assure that only the expected PCR products had been generated. Relative expression &#8805;3 was classified as overexpression. Data were normalized and analyzed using the method described by Chang <italic>et al</italic>., and the ATCC 9689 was used as a calibrator [<xref ref-type="bibr" rid="pone.0220671.ref031">31</xref>].</p>
<table-wrap id="pone.0220671.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220671.t001</object-id>
<label>Table 1</label> <caption><title>Primer pairs used to amplify the genes studied by real-time RT-PCR.</title></caption>
<alternatives>
<graphic id="pone.0220671.t001g" mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0220671.t001" ns0:type="simple" />
<table>
<colgroup>
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
</colgroup>
<thead>
<tr>
<th align="left">Target gene</th>
<th align="left">5&#8242;primer</th>
<th align="left">3&#8242;primer</th>
<th align="left">Source</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><italic>rrs</italic></td>
<td align="left"><monospace>GGGAGACTTGAGTGCAGGAG</monospace></td>
<td align="left"><monospace>GTGCCTCAGCGTCAGTTACA</monospace></td>
<td align="center">[<xref ref-type="bibr" rid="pone.0220671.ref043">43</xref>]</td>
</tr>
<tr>
<td align="left"><italic>spoA</italic></td>
<td align="left"><monospace>CTCAAAGCGCAATAAATCTAGGAGC</monospace></td>
<td align="left"><monospace>TTGAGTCTCTTGAACTGGTCTAGG</monospace></td>
<td align="center">[<xref ref-type="bibr" rid="pone.0220671.ref044">44</xref>]</td>
</tr>
<tr>
<td align="left"><italic>sigH</italic></td>
<td align="left"><monospace>GTTGGTAGCAAAAGAAAAAAGTTATGAG</monospace></td>
<td align="left"><monospace>GTACTCTAGTGCTATTTTATCCCCTTCAC</monospace></td>
<td align="center">[<xref ref-type="bibr" rid="pone.0220671.ref045">45</xref>]</td>
</tr>
<tr>
<td align="left"><italic>slpA</italic></td>
<td align="left"><monospace>AATGATAAAGCATTTGTAGTTGGTG</monospace></td>
<td align="left"><monospace>TATTGGAGTAGCATCTCCATC</monospace></td>
<td align="center">[<xref ref-type="bibr" rid="pone.0220671.ref043">43</xref>]</td>
</tr>
<tr>
<td align="left"><italic>cwp84</italic></td>
<td align="left"><monospace>TGGGCAACTGGTGGAAAATA</monospace></td>
<td align="left"><monospace>TAGTTGCACCTTGTGCCTCA</monospace></td>
<td align="center">[<xref ref-type="bibr" rid="pone.0220671.ref043">43</xref>]</td>
</tr>
<tr>
<td align="left"><italic>luxS</italic></td>
<td align="left"><monospace>GTGTACTTGATGGAGTAAAGGGAGA</monospace></td>
<td align="left"><monospace>TTCTACATCCCATTGGAGATAAGTC</monospace></td>
<td align="center">[<xref ref-type="bibr" rid="pone.0220671.ref046">46</xref>]</td>
</tr>
<tr>
<td align="left"><italic>agrD1</italic></td>
<td align="left"><monospace>TTTGCTAGCTCATTGGCACTT</monospace></td>
<td align="left"><monospace>GATTGCTGATTTCTTTGGGTACTT</monospace></td>
<td align="center">Primer3 software</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec013">
<title>Statistical analysis</title>
<p>Reduced susceptibility frequencies from planktonic and biofilm R-CDI cultures were compared with NR-CDI cultures using Pearson&#8217;s chi-square test and Fisher&#8217;s Exact test.</p>
<p>Differences in relative expression ratios mean of biofilm cultures from R-CDI and NR-CDI were analyzed using Student&#8217;s t-test. Non-parametric data were analyzed using the Mann-Whitney test and Spearman rank correlation test.</p>
<p>All statistical analysis were performed using the SPSS software package. A <italic>p</italic> value less than 0.05 was considered to be statistically significant.</p>
</sec>
</sec>
<sec id="sec014" sec-type="results">
<title>Results</title>
<sec id="sec015">
<title>Study population</title>
<p>In total, 254 patients with CDI (35.29%, female and 64.70%, male; age range, 15&#8211;85) were confirmed by PCR, with 102 isolates of <italic>C</italic>. <italic>difficile</italic> recovered. Patients with R-CDI had more significant exposure to antibiotics before CDI (p = 0.037) than patients with NR-CDI. Fluoroquinolones and vancomycin were more frequently used in patients with NR-CDI than in those with R-CDI (p = 0.000 and 0.024, respectively). Cephalosporins were more frequently used in patients with R-CDI than in NR-CDI (p = 0.048) (<xref ref-type="table" rid="pone.0220671.t002">Table 2</xref>).</p>
<table-wrap id="pone.0220671.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220671.t002</object-id>
<label>Table 2</label> <caption><title>Clinical characteristics of patients with R-CDI and NR-CDI.</title></caption>
<alternatives>
<graphic id="pone.0220671.t002g" mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0220671.t002" ns0:type="simple" />
<table>
<colgroup>
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
</colgroup>
<thead>
<tr>
<th align="left" />
<th align="left">R-CDI (n = 23)</th>
<th align="left">NR-CDI (n = 31)</th>
<th align="left"><italic>p</italic> value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Hospitalization</td>
<td align="left" />
<td align="left" />
<td align="left" />
</tr>
<tr>
<td align="left">Length of stay (mean days, range)</td>
<td align="left">29.55 (4&#8211;124)</td>
<td align="left">20.86 (4&#8211;59)</td>
<td align="char" char=".">0.181</td>
</tr>
<tr>
<td align="left">Intensive care unit, n (%)</td>
<td align="left">6 (26.09)</td>
<td align="left">10 (32.26)</td>
<td align="char" char=".">0.427</td>
</tr>
<tr>
<td align="left">Length of stay in ICU (mean days, range)</td>
<td align="left">14.77 (2&#8211;48)</td>
<td align="left">12.10 (2&#8211;48)</td>
<td align="char" char=".">0.460</td>
</tr>
<tr>
<td align="left">Prior antibiotics</td>
<td align="left" />
<td align="left" />
<td align="left" />
</tr>
<tr>
<td align="left">Any antibiotic, n (%)</td>
<td align="left">30 (96.77)</td>
<td align="left">22 (95.65)</td>
<td align="char" char=".">0.675</td>
</tr>
<tr>
<td align="left">Length of exposure (mean days, range)</td>
<td align="left">21.48 (1&#8211;100)</td>
<td align="left">13.52 (1&#8211;52)</td>
<td align="char" char=".">0.132</td>
</tr>
<tr>
<td align="left">No. of antibiotics (mean)</td>
<td align="left">3.65</td>
<td align="left">2.71</td>
<td align="char" char=".">0.037<xref ref-type="table-fn" rid="t002fn002">*</xref></td>
</tr>
<tr>
<td align="left">Cephalosporins</td>
<td align="left">12 (54.54)</td>
<td align="left">8 (27.59)</td>
<td align="char" char=".">0.048<xref ref-type="table-fn" rid="t002fn002">*</xref></td>
</tr>
<tr>
<td align="left">Clindamycin</td>
<td align="left">18 (81.82)</td>
<td align="left">21 (72.41)</td>
<td align="char" char=".">0.329</td>
</tr>
<tr>
<td align="left">Macrolides</td>
<td align="left">21 (95.45)</td>
<td align="left">27 (91.10)</td>
<td align="char" char=".">0.605</td>
</tr>
<tr>
<td align="left">Fluoroquinolones</td>
<td align="left">10 (45.45)</td>
<td align="left">27 (91.10)</td>
<td align="char" char=".">0.000<xref ref-type="table-fn" rid="t002fn002">*</xref></td>
</tr>
<tr>
<td align="left">Vancomycin</td>
<td align="left">9 (40.91)</td>
<td align="left">21 (72.41)</td>
<td align="char" char=".">0.024<xref ref-type="table-fn" rid="t002fn002">*</xref></td>
</tr>
<tr>
<td align="left">Metronidazole</td>
<td align="left">19 (86.36)</td>
<td align="left">25 (86.21)</td>
<td align="char" char=".">0.657</td>
</tr>
<tr>
<td align="left">Carbapenems</td>
<td align="left">14 (63.64)</td>
<td align="left">17 (58.62)</td>
<td align="char" char=".">0.472</td>
</tr>
<tr>
<td align="left">CDI treatment</td>
<td align="left" />
<td align="left" />
<td align="left" />
</tr>
<tr>
<td align="left">Vancomycin</td>
<td align="left">19 (86.36)</td>
<td align="left">24 (80.00)</td>
<td align="char" char=".">0.490</td>
</tr>
<tr>
<td align="left">Metronidazole</td>
<td align="left">13 (59.09)</td>
<td align="left">19 (63.33)</td>
<td align="char" char=".">0.415</td>
</tr>
<tr>
<td align="left">Metronidazole/vancomycin</td>
<td align="left">10 (45.45)</td>
<td align="left">16 (56.33)</td>
<td align="char" char=".">0.390</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>Data are no. (%) of patients, unless otherwise noted.</p></fn>
<fn id="t002fn002"><p>*Significant difference <italic>p</italic> value &lt;0.05</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec016">
<title>Culture and ribotyping</title>
<p>Sixty-six isolates (64.70%) of patients with NR-CDI and 36 (35.29%) of patients with R-CDI were obtained. Most of the isolates were found to be ribotype 027 (83/102, 81.37%). The other isolates were found to be ribotypes 003 and 002 (3/102, 2.94% each); 001, 014, 078, 220, and 076 (2/102, 1.96% each one); and 353 (1/102, 0.98%) (<xref ref-type="table" rid="pone.0220671.t003">Table 3</xref>). No significant differences in ribotype distribution between the R-CDI and NR-CDI groups was detected (p = 0.476).</p>
<table-wrap id="pone.0220671.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220671.t003</object-id>
<label>Table 3</label> <caption><title>Ribotype distribution between R-CDI and NR-CDI strains.</title></caption>
<alternatives>
<graphic id="pone.0220671.t003g" mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0220671.t003" ns0:type="simple" />
<table>
<colgroup>
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
</colgroup>
<thead>
<tr>
<th align="left" />
<th align="left">Genotype</th>
<th align="left">PCR-Ribotype (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="3">R-CDI (n = 36)</td>
<td align="left"><italic>tcdA</italic><sup>+</sup>, <italic>tcdB</italic><sup>+</sup>, <italic>tcdC</italic> &#916;18+, <italic>cdtA</italic><sup>+</sup>/<italic>cdtB</italic><sup>+</sup></td>
<td align="left">027 (30)</td>
</tr>
<tr>
<td align="left"><italic>tcdA</italic><sup>+</sup>, <italic>tcdB</italic><sup>+</sup>, <italic>tcdC</italic> &#916;18&#8722;, <italic>cdtA</italic><sup>-</sup>/<italic>cdtB</italic><sup>-</sup></td>
<td align="left">003 (1), 001 (1), 076 (1), NT (2)</td>
</tr>
<tr>
<td align="left"><italic>tcdA</italic><sup>+</sup>, <italic>tcdB</italic><sup>+</sup>, <italic>tcdC</italic> &#916;18&#8722;, <italic>cdtA</italic><sup><italic>+</italic></sup>/<italic>cdtB</italic><sup>+</sup></td>
<td align="left">353 (1)</td>
</tr>
<tr>
<td align="left" rowspan="3">NR-CDI (n = 66)</td>
<td align="left"><italic>tcdA</italic><sup>+</sup>, <italic>tcdB</italic><sup>+</sup>, <italic>tcdC</italic> &#916;18+, <italic>cdtA</italic><sup>+</sup>/<italic>cdtB</italic><sup>+</sup> <italic>tcdA</italic><sup>+</sup>, <italic>tcdB</italic><sup>+</sup>,</td>
<td align="left">027 (53),</td>
</tr>
<tr>
<td align="left"><italic>tcdA</italic><sup>+</sup>, <italic>tcdB</italic><sup>+</sup>, <italic>tcdC</italic> &#916;18&#8722;, <italic>cdtA</italic><sup>-</sup>/<italic>cdtB</italic><sup><italic>-</italic></sup></td>
<td align="left">002 (3), 014 (2) 003 (2), 220 (2), 076 (1), NT (1)</td>
</tr>
<tr>
<td align="left"><italic>tcdA</italic><sup>+</sup>, <italic>tcdB</italic><sup>+</sup>, <italic>tcdC</italic> &#916;39+, <italic>cdtA</italic><sup>+</sup>/<italic>cdtB</italic><sup>+</sup></td>
<td align="left">078 (2)</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec017">
<title><italic>C</italic>. <italic>difficile</italic> biofilm sporulation</title>
<p>In the <italic>C</italic>. <italic>difficile</italic> biofilm model, the majority of <italic>C</italic>. <italic>difficile</italic> isolates were producers of biofilm (100/102), with 80.55% of R-CDI isolates and 90.90% of NR-CDI isolates being strongly adherent. No differences were detected in biofilm production among the isolates of R-CDI and NR-CDI (AIs geometric mean [GM], 53.87 and 54.06, respectively; p = 0.579).</p>
<p>Sporulation was higher in R-CDI than in NR-CDI isolates (5 log<sub>10</sub> CFU/biofilm vs. 3.85 log<sub>10</sub> CFU/biofilm; p = 0.015).</p>
</sec>
<sec id="sec018">
<title><italic>C</italic>. <italic>difficile</italic>&#8211;microbiota biofilm and sporulation</title>
<p>In the biofilm of <italic>C</italic>. <italic>difficile</italic>&#8211;microbiota, no difference was detected in biofilm production among the isolates of R-CDI and NR-CDI (AIs GM, 33.04 and 32.89, respectively; p = 0.677).</p>
<p>No significant difference was detected in sporulation between the R-CDI and NR-CDI isolates (6.21 log<sub>10</sub> and 5.54 log<sub>10</sub> CFU/biofilm, respectively; p = 0.565).</p>
</sec>
<sec id="sec019">
<title>Minimum inhibitory concentrations</title>
<p>Drug susceptibility was evaluated on a selection of 65 isolates (26, R-CDI; 39, NR-CDI), and more than 70% of the isolates were resistant to ciprofloxacin (&#8805;8 mg/L), moxifloxacin (&#8805;8 mg/L), erythromycin (&#8805;8 mg/L), clindamycin (&#8805;8), and rifampin (&#8805;32 mg/L). All isolates were susceptible to tetracycline (&#8804;4 mg/L) and metronidazole (&#8804;8 mg/L).</p>
<p>The isolates from R-CDI patients showed a greater reduced susceptibility to vancomycin (&gt;2 mg/L) than the isolates from NR-CDI patients (27.78 and 9.09%, respectively). No other difference was observed between the R-CDI and NR-CDI isolates (<xref ref-type="table" rid="pone.0220671.t004">Table 4</xref>).</p>
<table-wrap id="pone.0220671.t004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220671.t004</object-id>
<label>Table 4</label> <caption><title>Antimicrobial susceptibility (mg/L) from R-CDI and NR-CDI strains.</title></caption>
<alternatives>
<graphic id="pone.0220671.t004g" mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0220671.t004" ns0:type="simple" />
<table>
<colgroup>
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
</colgroup>
<thead>
<tr>
<th align="left" colspan="2">Antimicrobial agent</th>
<th align="left">R-CDI</th>
<th align="left">NR-CDI</th>
<th align="left"><italic>p</italic> value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="4">Ciprofloxacin</td>
<td align="left">GM</td>
<td align="left">111.43</td>
<td align="left">61.71</td>
<td align="left" />
</tr>
<tr>
<td align="left">Range</td>
<td align="left">8-&gt;128</td>
<td align="left">1-&gt;128</td>
<td align="left" />
</tr>
<tr>
<td align="left">MIC<sub>90</sub></td>
<td align="left">&gt;128</td>
<td align="left">&gt;128</td>
<td align="left" />
</tr>
<tr>
<td align="left">Resistant (%)</td>
<td align="left">96.15</td>
<td align="left">89.74</td>
<td align="left">0.342</td>
</tr>
<tr>
<td align="left" rowspan="4">Moxifloxacin</td>
<td align="left">GM</td>
<td align="left">18.78</td>
<td align="left">14.22</td>
<td align="left" />
</tr>
<tr>
<td align="left">Range</td>
<td align="left">1&#8211;32</td>
<td align="left">1&#8211;32</td>
<td align="left" />
</tr>
<tr>
<td align="left">MIC<sub>90</sub></td>
<td align="left">32.00</td>
<td align="left">32.00</td>
<td align="left" />
</tr>
<tr>
<td align="left">Resistant (%)</td>
<td align="left">92.31</td>
<td align="left">87.23</td>
<td align="left">0.506</td>
</tr>
<tr>
<td align="left" rowspan="4">Erythromycin</td>
<td align="left">GM</td>
<td align="left">190.21</td>
<td align="left">87.70</td>
<td align="left" />
</tr>
<tr>
<td align="left">Range</td>
<td align="left">1-&gt;128</td>
<td align="left">1-&gt;128</td>
<td align="left" />
</tr>
<tr>
<td align="left">MIC<sub>90</sub></td>
<td align="left">&gt;128</td>
<td align="left">&gt;128</td>
<td align="left" />
</tr>
<tr>
<td align="left">Resistant (%)</td>
<td align="left">81.81</td>
<td align="left">95.23</td>
<td align="left">0.152</td>
</tr>
<tr>
<td align="left" rowspan="4">Clindamycin</td>
<td align="left">GM</td>
<td align="left">150.97</td>
<td align="left">66.75</td>
<td align="left" />
</tr>
<tr>
<td align="left">Range</td>
<td align="left">1-&gt;128</td>
<td align="left">0.5-&gt;128</td>
<td align="left" />
</tr>
<tr>
<td align="left">MIC<sub>90</sub></td>
<td align="left">&gt;128</td>
<td align="left">&gt;128</td>
<td align="left" />
</tr>
<tr>
<td align="left">Resistant (%)</td>
<td align="left">90.48</td>
<td align="left">81.82</td>
<td align="left">0.383</td>
</tr>
<tr>
<td align="left" rowspan="4">Vancomycin</td>
<td align="left">GM</td>
<td align="left">2.16</td>
<td align="left">1.76</td>
<td align="left" />
</tr>
<tr>
<td align="left">Range</td>
<td align="left">1&#8211;4</td>
<td align="left">0.25&#8211;4</td>
<td align="left" />
</tr>
<tr>
<td align="left">MIC<sub>90</sub></td>
<td align="left">4.00</td>
<td align="left">2.00</td>
<td align="left" />
</tr>
<tr>
<td align="left">Resistant (%)</td>
<td align="left">27.78</td>
<td align="left">9.09</td>
<td align="left">0.013<xref ref-type="table-fn" rid="t004fn002">*</xref></td>
</tr>
<tr>
<td align="left" rowspan="4">Metronidazole</td>
<td align="left">GM</td>
<td align="left">1.59</td>
<td align="left">1.39</td>
<td align="left" />
</tr>
<tr>
<td align="left">Range</td>
<td align="left">0.25&#8211;4</td>
<td align="left">0.25&#8211;4</td>
<td align="left" />
</tr>
<tr>
<td align="left">MIC<sub>90</sub></td>
<td align="left">4.00</td>
<td align="left">2.00</td>
<td align="left" />
</tr>
<tr>
<td align="left">Resistant (%)</td>
<td align="left">0.00</td>
<td align="left">0.00</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left" rowspan="4">Linezolid</td>
<td align="left">GM</td>
<td align="left">3.92</td>
<td align="left">4.00</td>
<td align="left" />
</tr>
<tr>
<td align="left">Range</td>
<td align="left">0.5&#8211;32</td>
<td align="left">0.03&#8211;32</td>
<td align="left" />
</tr>
<tr>
<td align="left">MIC<sub>90</sub></td>
<td align="left">16.00</td>
<td align="left">16.00</td>
<td align="left" />
</tr>
<tr>
<td align="left">Resistant (%)</td>
<td align="left">38.89</td>
<td align="left">19.70</td>
<td align="left">0.036<xref ref-type="table-fn" rid="t004fn002">*</xref></td>
</tr>
<tr>
<td align="left" rowspan="4">Rifampin</td>
<td align="left">GM</td>
<td align="left">13.55</td>
<td align="left">16.02</td>
<td align="left" />
</tr>
<tr>
<td align="left">Range</td>
<td align="left">0.001-&gt;128</td>
<td align="left">0.002-&gt;128</td>
<td align="left" />
</tr>
<tr>
<td align="left">MIC<sub>90</sub></td>
<td align="left">&gt;128</td>
<td align="left">128.00</td>
<td align="left" />
</tr>
<tr>
<td align="left">Resistant (%)</td>
<td align="left">70.59</td>
<td align="left">79.41</td>
<td align="left">0.484</td>
</tr>
<tr>
<td align="left" rowspan="4">Tetracycline</td>
<td align="left">GM</td>
<td align="left">0.26</td>
<td align="left">0.16</td>
<td align="left" />
</tr>
<tr>
<td align="left">Range</td>
<td align="left">0.06&#8211;8</td>
<td align="left">0.06&#8211;8</td>
<td align="left" />
</tr>
<tr>
<td align="left">MIC<sub>90</sub></td>
<td align="left">4.00</td>
<td align="left">0.13</td>
<td align="left" />
</tr>
<tr>
<td align="left">Resistant (%)</td>
<td align="left">0.00</td>
<td align="left">0.00</td>
<td align="left">NA</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t004fn001"><p>Breakpoints were as follows: moxifloxacin and clindamycin &#8805;8 mg/L, tetracycline &#8805;16 mg/L, metronidazole &#8805;32 mg/L according to CLSI (2019); vancomycin &gt;2 mg/L according to EUCAST (2019), erythromycin &#8805;8 mg/L according to CLSI (2013); ciprofloxacin, &#8805;8 mg/L [<xref ref-type="bibr" rid="pone.0220671.ref028">28</xref>], linezolid &#8805;16 mg/L [<xref ref-type="bibr" rid="pone.0220671.ref029">29</xref>] and rifampicin &#8805;32 mg/L [<xref ref-type="bibr" rid="pone.0220671.ref030">30</xref>].</p></fn>
<fn id="t004fn002"><p>*Significant difference <italic>p</italic> value &lt;0.05</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec020">
<title>Minimum inhibitory concentrations of the biofilm</title>
<p>In <italic>C</italic>. <italic>difficile</italic> biofilm isolates without microbiota, a reduced susceptibility to vancomycin was observed in 91.0% (101/102) of isolates and to linezolid in 89.21% (91/102) of isolates.</p>
<p>The BMICs were up to 100-fold higher for vancomycin and 20-fold higher for linezolid than the corresponding MICs. No differences between R-CDI and NR-CDI isolates were observed (<xref ref-type="table" rid="pone.0220671.t005">Table 5</xref>).</p>
<table-wrap id="pone.0220671.t005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220671.t005</object-id>
<label>Table 5</label> <caption><title>Distribution of MICs and BMICs between R-CDI and NR-CDI strains.</title></caption>
<alternatives>
<graphic id="pone.0220671.t005g" mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0220671.t005" ns0:type="simple" />
<table>
<colgroup>
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
</colgroup>
<thead>
<tr>
<th align="left" />
<th align="left" />
<th align="left" colspan="3">Vancomycin</th>
<th align="left" />
<th align="left" colspan="3">Linezolid</th>
<th align="left" />
</tr>
<tr>
<th align="left" />
<th align="left" />
<th align="left">Range</th>
<th align="left">GM</th>
<th align="left">Resistant (%)</th>
<th align="left"><italic>p</italic> value</th>
<th align="left">Range</th>
<th align="left">GM</th>
<th align="left">Resistant (%)</th>
<th align="left"><italic>p</italic> value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="2">R-CDI</td>
<td align="left">MIC</td>
<td align="left">1.00&#8211;4.00</td>
<td align="char" char=".">1.88</td>
<td align="left">10/36 (27.78)</td>
<td align="char" char=".">0.000</td>
<td align="left">0.50&#8211;32.0</td>
<td align="char" char=".">3.92</td>
<td align="left">3/36 (8.33)</td>
<td align="char" char=".">0.000<xref ref-type="table-fn" rid="t005fn002">**</xref></td>
</tr>
<tr>
<td align="left">BMIC</td>
<td align="left">2.00&#8211;256</td>
<td align="char" char=".">109.08</td>
<td align="left">35/36 (97.22)</td>
<td align="left" />
<td align="left">4.00&#8211;256.0</td>
<td align="char" char=".">87.34</td>
<td align="left">29/36 (80.55)</td>
<td align="left" />
</tr>
<tr>
<td align="left" rowspan="2">NR-CDI</td>
<td align="left">MIC</td>
<td align="left">0.25&#8211;4.00</td>
<td align="char" char=".">1.85</td>
<td align="left">6/66 (9.09)</td>
<td align="char" char=".">0.000</td>
<td align="left">0.03&#8211;32.0</td>
<td align="char" char=".">4.02</td>
<td align="left">13/66 (20.0)</td>
<td align="char" char=".">0.000<xref ref-type="table-fn" rid="t005fn002">**</xref></td>
</tr>
<tr>
<td align="left">BMIC</td>
<td align="left">2.00&#8211;256</td>
<td align="char" char=".">108.35</td>
<td align="left">66/66 (100)</td>
<td align="left" />
<td align="left">2.00&#8211;256.0</td>
<td align="char" char=".">89.63</td>
<td align="left">62/66 (95.38)</td>
<td align="left" />
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t005fn001"><p>Data are mg/L of an antimicrobial agent unless otherwise noted.</p></fn>
<fn id="t005fn002"><p>**Significant difference <italic>p</italic> value &lt;0.01</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec021">
<title>Expression of <italic>spo0A</italic>, <italic>sigH</italic>, <italic>slpA</italic>, <italic>cwp84</italic>, <italic>agrD</italic><sub><italic>1</italic></sub>, and <italic>luxS</italic></title>
<p>The relative expression of <italic>spo0A</italic>, <italic>sigH</italic>, <italic>cwp84</italic>, and <italic>agrD1</italic> was higher in R-CDI than in NR-CDI isolates (<xref ref-type="fig" rid="pone.0220671.g001">Fig 1</xref>). Overexpression of <italic>spo0A</italic> (70%, 7/10), <italic>sigH</italic> (70%, 7/10), <italic>cwp84</italic> (40%, 4/10), and <italic>agrD</italic><sub><italic>1</italic></sub> (70%, 7/10) was higher in R-CDI than in NR-CDI isolates. No significant difference was detected in the expression levels of <italic>slpA</italic> and <italic>luxS</italic> between R-CDI and NR-CDI isolates (<xref ref-type="fig" rid="pone.0220671.g001">Fig 1</xref>).</p>
<fig id="pone.0220671.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220671.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Expression levels of <italic>spo0A</italic>, <italic>sigH</italic>, <italic>cwp84</italic>, <italic>slpA</italic>, <italic>agrD1</italic>, and <italic>luxS</italic> transcripts between R-CDI and NR-CDI strains.</title>
<p>Relative mRNA transcripts expression means of <italic>spo0A</italic> (<italic>p</italic> = 0.003), <italic>sigH</italic> (<italic>p</italic> = 0.007), <italic>cwp84</italic> (<italic>p</italic> = 0.001), <italic>slpA</italic> (<italic>p</italic> = 0.066), <italic>agrD</italic><sub><italic>1</italic></sub> (<italic>p</italic> = 0.001) and <italic>luxS</italic> (<italic>p</italic> = 0.400) from R-CDI and NR-CDI strains. **Significant difference p value &lt;0.01.</p>
</caption>
<graphic mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0220671.g001" ns0:type="simple" />
</fig>
</sec>
</sec>
<sec id="sec022" sec-type="conclusions">
<title>Discussion</title>
<p>Although some bacterial species that cause recurrent or chronic infections have been studied for their ability to form biofilms <italic>in vivo</italic> and <italic>in vitro</italic> [<xref ref-type="bibr" rid="pone.0220671.ref006">6</xref>], <italic>C</italic>. <italic>difficile</italic> biofilms have not been widely studied. In the present study, we evaluated biofilm formation by <italic>C</italic>. <italic>difficile</italic> and detected that most isolates were biofilm producers (strong adherent), independent of the ribotype or whether the strains were isolated from R-CDI or NR-CDI patients. These results reflect those of other previous studies that found no correlation between the ribotype, the strain virulence, or relapse of infection [<xref ref-type="bibr" rid="pone.0220671.ref016">16</xref>].</p>
<p>The expression of quorum sensing regulators and adhesion-associated factors were determined from biofilm culture. <italic>agrD1</italic> and <italic>cwp84</italic> were overexpressed in R-CDI isolates, both of which were previously shown to regulate colonization, virulence, and relapses in <italic>in vivo</italic> models [<xref ref-type="bibr" rid="pone.0220671.ref008">8</xref>, <xref ref-type="bibr" rid="pone.0220671.ref016">16</xref>, <xref ref-type="bibr" rid="pone.0220671.ref018">18</xref>&#8211;<xref ref-type="bibr" rid="pone.0220671.ref020">20</xref>]. By contrast, <italic>luxS</italic> and <italic>slpA</italic> expression was similar in R-CDI and NR-CDI isolates. It would be valuable in the future, to analyze the transcription of toxins A and B involving isolates overexpressing <italic>agrD1</italic> and <italic>cwp84</italic> from R-CDI and NR-CDI isolates.</p>
<p>Differences in spore formation in biofilms aged 7&#8211;10 days compared to vegetative cultures have been reported previously, including higher viable counts, higher temperature tolerance, and pleiomorphic biofilm structures (thin, thick exosporium surrounding the spores in the biofilm) [<xref ref-type="bibr" rid="pone.0220671.ref032">32</xref>, <xref ref-type="bibr" rid="pone.0220671.ref033">33</xref>]. Further studies to compare germination efficiency with co-germinants in this biofilm model need to be done. In the present study, we analyzed 7-day old biofilms and found that sporulation was greater in the R-CDI strains than in the NR-CDI strains. In addition, sporulation was associated with overexpression of the key regulators of the initial steps of the sporulation pathway, <italic>spo0A</italic> and <italic>sigH</italic>, suggesting their involvement in the overproduction of spores in the biofilm. According to our results, the production of spores can be associated with recurrent CDI isolates.</p>
<p>In the present study, a high proportion of resistance was detected against ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and rifampin, and all isolates were susceptible to tetracycline and metronidazole. No differences were detected between NR-CDI and R-CDI strains for these antimicrobial susceptibilities.</p>
<p>Conversely, lower susceptibility to linezolid was observed in R-CDI strains than in NR-CDI strains, and this result is relevant because linezolid is considered to be a possible drug for treatment with CDI. Interestingly, our study population has no records of exposure to this antimicrobial agent in the 12 weeks before the diagnosis of CDI. The <italic>cfr</italic> gene has been associated with resistance to linezolid and has been detected in <italic>C</italic>. <italic>difficile</italic> with a MIC up to 16 mg/L [<xref ref-type="bibr" rid="pone.0220671.ref034">34</xref>]. Further studies are underway to clarify the molecular mechanisms associated with this drug resistance.</p>
<p>In our study, the isolates from R-CDI patients showed lower susceptibility to vancomycin (MIC &gt; 2 mg/L) more frequently than isolates from NR-CDI patients (27.78 and 9.09%, respectively); and this result is important given the wide use of vancomycin for treatment of CDI.</p>
<p>High MICs have been reported for moxifloxacin, rifampicin, vancomycin, and clindamycin in ribotypes 001, 017, 027, 176, 078, and 014 [<xref ref-type="bibr" rid="pone.0220671.ref035">35</xref>, <xref ref-type="bibr" rid="pone.0220671.ref036">36</xref>]. In the present study, high MICs were detected for the same antibiotics in addition to ciprofloxacin and erythromycin. Most of the isolates obtained were ribotype 027. No difference in ribotype was found between the R-CDI and NR-CDI groups. In our population, 027 strains are associated with higher mortality rates and greater probability of R-CDI [<xref ref-type="bibr" rid="pone.0220671.ref037">37</xref>].</p>
<p><italic>C</italic>. <italic>difficile</italic> isolates from the present study had high exposure to clindamycin, and this exposure has been associated in prior studies with a high excretion of <italic>C</italic>. <italic>difficile</italic> spores [<xref ref-type="bibr" rid="pone.0220671.ref038">38</xref>]. Therefore, the high use of clindamycin in our clinical setting of Mexico may be associated with the high sporulation detected.</p>
<p>In a 3-day biofilm model of <italic>C</italic>. <italic>difficile</italic>, the susceptibility to vancomycin has been reported, with BMICs up to 100 times higher than the corresponding planktonic MICs [<xref ref-type="bibr" rid="pone.0220671.ref008">8</xref>, <xref ref-type="bibr" rid="pone.0220671.ref039">39</xref>, <xref ref-type="bibr" rid="pone.0220671.ref040">40</xref>]. In the present study, we confirmed a reduced susceptibility to vancomycin in most strains, with BMICs up to 100 times higher than MICs. Reduced susceptibility of <italic>C</italic>. <italic>difficile</italic> [<xref ref-type="bibr" rid="pone.0220671.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0220671.ref041">41</xref>] and BMIC values six times higher than MIC have been reported for metronidazole [<xref ref-type="bibr" rid="pone.0220671.ref014">14</xref>]. Despite our patients having been treated with metronidazole before the diagnosis of CDI, we did not find isolates with reduced susceptibility to this antimicrobial agent in either planktonic or biofilm MIC experiments.</p>
<p>Several risk factors have been described for the development of CDI [<xref ref-type="bibr" rid="pone.0220671.ref042">42</xref>]. In our study, the consumption of cephalosporins and a greater number of previous antibiotics were risk factors for R-CDI. In addition, patients with NR-CDI more frequently used fluoroquinolones (p = 0.000) and vancomycin (p = 0.024) than those with R-CDI.</p>
<p>The primary limitation of this study was that cultures were not performed on fresh samples. Instead, they were frozen and stored at &#8722;20&#176;C for up to two years with at least two freeze-thaw cycles, which could explain the low recovery of <italic>C</italic>. <italic>difficile</italic>.</p>
<p>In conclusion, the sporulation and overexpression of <italic>sigH</italic>, <italic>spo0A</italic>, and <italic>agrD</italic><sub><italic>1</italic></sub> were greater in R-CDI than in NR-CDI isolates. The R-CDI isolates had more reduced susceptibility to vancomycin and linezolid than the NR-CDI isolates in both planktonic cells and biofilm isolates. These factors may affect the recurrence of the infection because a greater sporulation in the protected biofilm may facilitate less spore washout from the gut and a higher likelihood of <italic>C</italic>. <italic>difficile</italic> remaining after CDI therapy has ceased.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0220671.ref001"><label>1</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Lessa</surname> <given-names>FC</given-names></name>, <name name-style="western"><surname>Mu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Bamberg</surname> <given-names>WM</given-names></name>, <name name-style="western"><surname>Beldavs</surname> <given-names>ZG</given-names></name>, <name name-style="western"><surname>Dumyati</surname> <given-names>GK</given-names></name>, <name name-style="western"><surname>Dunn</surname> <given-names>JR</given-names></name>, <etal>et al</etal>. <article-title>Burden of <italic>Clostridium difficile</italic> infection in the United States</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>(<issue>9</issue>):<fpage>825</fpage>&#8211;<lpage>34</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1056/NEJMoa1408913" ns0:type="simple">10.1056/NEJMoa1408913</ext-link></comment> <object-id pub-id-type="pmid">25714160</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref002"><label>2</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>McFarland</surname> <given-names>LV</given-names></name>, <name name-style="western"><surname>Elmer</surname> <given-names>GW</given-names></name>, <name name-style="western"><surname>Surawicz</surname> <given-names>CM</given-names></name>. <article-title>Breaking the cycle: treatment strategies for 163 cases of recurrent <italic>Clostridium difficile</italic> disease</article-title>. <source>Am J Gastroenterol</source>. <year>2002</year>;<volume>97</volume>(<issue>7</issue>):<fpage>1769</fpage>&#8211;<lpage>75</lpage>. <object-id pub-id-type="pmid">12135033</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref003"><label>3</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Mac Aogain</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Moloney</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Kilkenny</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kelleher</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kelleghan</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Boyle</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Whole-genome sequencing improves discrimination of relapse from reinfection and identifies transmission events among patients with recurrent <italic>Clostridium difficile</italic> infections</article-title>. <source>J Hosp Infect</source>. <year>2015</year>;<volume>90</volume>(<issue>2</issue>):<fpage>108</fpage>&#8211;<lpage>16</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.jhin.2015.01.021" ns0:type="simple">10.1016/j.jhin.2015.01.021</ext-link></comment> <object-id pub-id-type="pmid">25935700</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref004"><label>4</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Figueroa</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Johnson</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sambol</surname> <given-names>SP</given-names></name>, <name name-style="western"><surname>Goldstein</surname> <given-names>EJ</given-names></name>, <name name-style="western"><surname>Citron</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Gerding</surname> <given-names>DN</given-names></name>. <article-title>Relapse versus reinfection: recurrent <italic>Clostridium difficil</italic>e infection following treatment with fidaxomicin or vancomycin</article-title>. <source>Clin Infect Dis</source>. <year>2012</year>;<volume>55</volume> <issue>Suppl 2</issue>:<fpage>S104</fpage>&#8211;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1093/cid/cis357" ns0:type="simple">10.1093/cid/cis357</ext-link></comment> <object-id pub-id-type="pmid">22752857</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref005"><label>5</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Gil</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Pizarro-Guajardo</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Alvarez</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Garavaglia</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Paredes-Sabja</surname> <given-names>D</given-names></name>. <article-title><italic>Clostridium difficile</italic> recurrent infection: possible implication of TA systems</article-title>. <source>Future Microbiol</source>. <year>2015</year>;<volume>10</volume>(<issue>10</issue>):<fpage>1649</fpage>&#8211;<lpage>57</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.2217/fmb.15.94" ns0:type="simple">10.2217/fmb.15.94</ext-link></comment> <object-id pub-id-type="pmid">26439907</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref006"><label>6</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Bjarnsholt</surname> <given-names>T</given-names></name>. <article-title>The role of bacterial biofilms in chronic infections</article-title>. <source>APMIS Suppl</source>. <year>2013</year>;(<issue>136</issue>):<fpage>1</fpage>&#8211;<lpage>51</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1111/apm.12099" ns0:type="simple">10.1111/apm.12099</ext-link></comment> <object-id pub-id-type="pmid">23635385</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref007"><label>7</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Dawson</surname> <given-names>LF</given-names></name>, <name name-style="western"><surname>Valiente</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Faulds-Pain</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Donahue</surname> <given-names>EH</given-names></name>, <name name-style="western"><surname>Wren</surname> <given-names>BW</given-names></name>. <article-title>Characterisation of <italic>Clostridium difficile</italic> biofilm formation, a role for Spo0A</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>12</issue>):<fpage>e50527</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1371/journal.pone.0050527" ns0:type="simple">10.1371/journal.pone.0050527</ext-link></comment> <object-id pub-id-type="pmid">23236376</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref008"><label>8</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Ethapa</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Leuzzi</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Ng</surname> <given-names>YK</given-names></name>, <name name-style="western"><surname>Baban</surname> <given-names>ST</given-names></name>, <name name-style="western"><surname>Adamo</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Kuehne</surname> <given-names>SA</given-names></name>, <etal>et al</etal>. <article-title>Multiple factors modulate biofilm formation by the anaerobic pathogen <italic>Clostridium difficile</italic></article-title>. <source>J Bacteriol</source>. <year>2013</year>;<volume>195</volume>(<issue>3</issue>):<fpage>545</fpage>&#8211;<lpage>55</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/JB.01980-12" ns0:type="simple">10.1128/JB.01980-12</ext-link></comment> <object-id pub-id-type="pmid">23175653</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref009"><label>9</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Donelli</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Vuotto</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Cardines</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Mastrantonio</surname> <given-names>P</given-names></name>. <article-title>Biofilm-growing intestinal anaerobic bacteria</article-title>. <source>FEMS Immunol Med Microbiol</source>. <year>2012</year>;<volume>65</volume>(<issue>2</issue>):<fpage>318</fpage>&#8211;<lpage>25</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1111/j.1574-695X.2012.00962.x" ns0:type="simple">10.1111/j.1574-695X.2012.00962.x</ext-link></comment> <object-id pub-id-type="pmid">22444687</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref010"><label>10</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Dapa</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Unnikrishnan</surname> <given-names>M</given-names></name>. <article-title>Biofilm formation by <italic>Clostridium difficile</italic></article-title>. <source>Gut Microbes</source>. <year>2013</year>;<volume>4</volume>(<issue>5</issue>):<fpage>397</fpage>&#8211;<lpage>402</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.4161/gmic.25862" ns0:type="simple">10.4161/gmic.25862</ext-link></comment> <object-id pub-id-type="pmid">23892245</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref011"><label>11</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Crowther</surname> <given-names>GS</given-names></name>, <name name-style="western"><surname>Chilton</surname> <given-names>CH</given-names></name>, <name name-style="western"><surname>Todhunter</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Nicholson</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Freeman</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Baines</surname> <given-names>SD</given-names></name>, <etal>et al</etal>. <article-title>Development and validation of a chemostat gut model to study both planktonic and biofilm modes of growth of <italic>Clostridium difficile</italic> and human microbiota</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>2</issue>):<fpage>e88396</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1371/journal.pone.0088396" ns0:type="simple">10.1371/journal.pone.0088396</ext-link></comment> <object-id pub-id-type="pmid">24516647</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref012"><label>12</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Deakin</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Clare</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Fagan</surname> <given-names>RP</given-names></name>, <name name-style="western"><surname>Dawson</surname> <given-names>LF</given-names></name>, <name name-style="western"><surname>Pickard</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>West</surname> <given-names>MR</given-names></name>, <etal>et al</etal>. <article-title>The <italic>Clostridium difficile spo0A</italic> gene is a persistence and transmission factor</article-title>. <source>Infect Immun</source>. <year>2012</year>;<volume>80</volume>(<issue>8</issue>):<fpage>2704</fpage>&#8211;<lpage>11</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/IAI.00147-12" ns0:type="simple">10.1128/IAI.00147-12</ext-link></comment> <object-id pub-id-type="pmid">22615253</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref013"><label>13</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Paredes-Sabja</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Cofre-Araneda</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Brito-Silva</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Pizarro-Guajardo</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sarker</surname> <given-names>MR</given-names></name>. <article-title><italic>Clostridium difficile</italic> spore-macrophage interactions: spore survival</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>8</issue>):<fpage>e43635</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1371/journal.pone.0043635" ns0:type="simple">10.1371/journal.pone.0043635</ext-link></comment> <object-id pub-id-type="pmid">22952726</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref014"><label>14</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Semenyuk</surname> <given-names>EG</given-names></name>, <name name-style="western"><surname>Laning</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Foley</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Johnston</surname> <given-names>PF</given-names></name>, <name name-style="western"><surname>Knight</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Gerding</surname> <given-names>DN</given-names></name>, <etal>et al</etal>. <article-title>Spore formation and toxin production in <italic>Clostridium difficile</italic> biofilms</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>1</issue>):<fpage>e87757</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1371/journal.pone.0087757" ns0:type="simple">10.1371/journal.pone.0087757</ext-link></comment> <object-id pub-id-type="pmid">24498186</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref015"><label>15</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Mora-Uribe</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Miranda-Cardenas</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Castro-Cordova</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Gil</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Calderon</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Fuentes</surname> <given-names>JA</given-names></name>, <etal>et al</etal>. <article-title>Characterization of the Adherence of <italic>Clostridium difficile</italic> Spores: The Integrity of the Outermost Layer Affects Adherence Properties of Spores of the Epidemic Strain R20291 to Components of the Intestinal Mucosa</article-title>. <source>Front Cell Infect Microbiol</source>. <year>2016</year>;<volume>6</volume>:<fpage>99</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.3389/fcimb.2016.00099" ns0:type="simple">10.3389/fcimb.2016.00099</ext-link></comment> <object-id pub-id-type="pmid">27713865</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref016"><label>16</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Pantaleon</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Soavelomandroso</surname> <given-names>AP</given-names></name>, <name name-style="western"><surname>Bouttier</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Briandet</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Roxas</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Chu</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>The <italic>Clostridium difficile</italic> Protease Cwp84 Modulates both Biofilm Formation and Cell-Surface Properties</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>4</issue>):<fpage>e0124971</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1371/journal.pone.0124971" ns0:type="simple">10.1371/journal.pone.0124971</ext-link></comment> <object-id pub-id-type="pmid">25922949</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref017"><label>17</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Saujet</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Monot</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Dupuy</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Soutourina</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Martin-Verstraete</surname> <given-names>I</given-names></name>. <article-title>The key sigma factor of transition phase, SigH, controls sporulation, metabolism, and virulence factor expression in <italic>Clostridium difficile</italic></article-title>. <source>J Bacteriol</source>. <year>2011</year>;<volume>193</volume>(<issue>13</issue>):<fpage>3186</fpage>&#8211;<lpage>96</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/JB.00272-11" ns0:type="simple">10.1128/JB.00272-11</ext-link></comment> <object-id pub-id-type="pmid">21572003</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref018"><label>18</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Martin</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Clare</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Goulding</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Faulds-Pain</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Barquist</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Browne</surname> <given-names>HP</given-names></name>, <etal>et al</etal>. <article-title>The <italic>agr</italic> locus regulates virulence and colonization genes in <italic>Clostridium difficile</italic> 027</article-title>. <source>J Bacteriol</source>. <year>2013</year>;<volume>195</volume>(<issue>16</issue>):<fpage>3672</fpage>&#8211;<lpage>81</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/JB.00473-13" ns0:type="simple">10.1128/JB.00473-13</ext-link></comment> <object-id pub-id-type="pmid">23772065</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref019"><label>19</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Darkoh</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Odo</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>DuPont</surname> <given-names>HL</given-names></name>. <article-title>Accessory Gene Regulator-1 Locus Is Essential for Virulence and Pathogenesis of <italic>Clostridium difficile</italic></article-title>. <source>MBio</source>. <year>2016</year>;<volume>7</volume>(<issue>4</issue>). <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/mBio.01237-16" ns0:type="simple">10.1128/mBio.01237-16</ext-link></comment> <object-id pub-id-type="pmid">27531912</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref020"><label>20</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Darkoh</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>DuPont</surname> <given-names>HL</given-names></name>, <name name-style="western"><surname>Norris</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Kaplan</surname> <given-names>HB</given-names></name>. <article-title>Toxin synthesis by <italic>Clostridium difficile</italic> is regulated through quorum signaling</article-title>. <source>MBio</source>. <year>2015</year>;<volume>6</volume>(<issue>2</issue>):<fpage>e02569</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/mBio.02569-14" ns0:type="simple">10.1128/mBio.02569-14</ext-link></comment> <object-id pub-id-type="pmid">25714717</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref021"><label>21</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Surawicz</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Brandt</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Binion</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Ananthakrishnan</surname> <given-names>AN</given-names></name>, <name name-style="western"><surname>Curry</surname> <given-names>SR</given-names></name>, <name name-style="western"><surname>Gilligan</surname> <given-names>PH</given-names></name>, <etal>et al</etal>. <article-title>Guidelines for diagnosis, treatment, and prevention of <italic>Clostridium difficile</italic> infections</article-title>. <source>Am J Gastroenterol</source>. <year>2013</year>;<volume>108</volume>(<issue>4</issue>):<fpage>478</fpage>&#8211;<lpage>98</lpage>; quiz 99. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1038/ajg.2013.4" ns0:type="simple">10.1038/ajg.2013.4</ext-link></comment> <object-id pub-id-type="pmid">23439232</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref022"><label>22</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Lemee</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Dhalluin</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Testelin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mattrat</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Maillard</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Lemeland</surname> <given-names>JF</given-names></name>, <etal>et al</etal>. <article-title>Multiplex PCR targeting <italic>tpi</italic> (triose phosphate isomerase), <italic>tcdA</italic> (Toxin A), and <italic>tcdB</italic> (Toxin B) genes for toxigenic culture of <italic>Clostridium difficile</italic></article-title>. <source>J Clin Microbiol</source>. <year>2004</year>;<volume>42</volume>(<issue>12</issue>):<fpage>5710</fpage>&#8211;<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/JCM.42.12.5710-5714.2004" ns0:type="simple">10.1128/JCM.42.12.5710-5714.2004</ext-link></comment> <object-id pub-id-type="pmid">15583303</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref023"><label>23</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Bidet</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Barbut</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Lalande</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Burghoffer</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Petit</surname> <given-names>JC</given-names></name>. <article-title>Development of a new PCR-ribotyping method for <italic>Clostridium difficile</italic> based on ribosomal RNA gene sequencing</article-title>. <source>FEMS Microbiol Lett</source>. <year>1999</year>;<volume>175</volume>(<issue>2</issue>):<fpage>261</fpage>&#8211;<lpage>6</lpage>. <ext-link ext-link-type="uri" ns0:href="http://www.ncbi.nlm.nih.gov/pubmed/10386377" ns0:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/10386377</ext-link>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1111/j.1574-6968.1999.tb13629.x" ns0:type="simple">10.1111/j.1574-6968.1999.tb13629.x</ext-link></comment></mixed-citation></ref>
<ref id="pone.0220671.ref024"><label>24</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Hammond</surname> <given-names>EN</given-names></name>, <name name-style="western"><surname>Donkor</surname> <given-names>ES</given-names></name>, <name name-style="western"><surname>Brown</surname> <given-names>CA</given-names></name>. <article-title>Biofilm formation of <italic>Clostridium difficile</italic> and susceptibility to Manuka honey</article-title>. <source>BMC Complement Altern Med</source>. <year>2014</year>;<volume>14</volume>:<fpage>329</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1186/1472-6882-14-329" ns0:type="simple">10.1186/1472-6882-14-329</ext-link></comment> <object-id pub-id-type="pmid">25181951</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref025"><label>25</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Stepanovic</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Vukovic</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Hola</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Di Bonaventura</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Djukic</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Cirkovic</surname> <given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci</article-title>. <source>APMIS</source>. <year>2007</year>;<volume>115</volume>(<issue>8</issue>):<fpage>891</fpage>&#8211;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1111/j.1600-0463.2007.apm_630.x" ns0:type="simple">10.1111/j.1600-0463.2007.apm_630.x</ext-link></comment> <object-id pub-id-type="pmid">17696944</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref026"><label>26</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Baines</surname> <given-names>SD</given-names></name>, <name name-style="western"><surname>O&#8217;Connor</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Freeman</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Fawley</surname> <given-names>WN</given-names></name>, <name name-style="western"><surname>Harmanus</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Mastrantonio</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Emergence of reduced susceptibility to metronidazole in <italic>Clostridium difficile</italic></article-title>. <source>J Antimicrob Chemother</source>. <year>2008</year>;<volume>62</volume>(<issue>5</issue>):<fpage>1046</fpage>&#8211;<lpage>52</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1093/jac/dkn313" ns0:type="simple">10.1093/jac/dkn313</ext-link></comment> <object-id pub-id-type="pmid">18693234</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref027"><label>27</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Freeman</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Stott</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Baines</surname> <given-names>SD</given-names></name>, <name name-style="western"><surname>Fawley</surname> <given-names>WN</given-names></name>, <name name-style="western"><surname>Wilcox</surname> <given-names>MH</given-names></name>. <article-title>Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic <italic>Clostridium difficile</italic> isolates in a large teaching hospital</article-title>. <source>J Antimicrob Chemother</source>. <year>2005</year>;<volume>56</volume>(<issue>5</issue>):<fpage>988</fpage>&#8211;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1093/jac/dki357" ns0:type="simple">10.1093/jac/dki357</ext-link></comment> <object-id pub-id-type="pmid">16195254</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref028"><label>28</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Buchler</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Rampini</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Stelling</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ledergerber</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Peter</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Schweiger</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Antibiotic susceptibility of <italic>Clostridium difficile</italic> is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich</article-title>. <source>BMC Infect Dis</source>. <year>2014</year>;<volume>14</volume>:<fpage>607</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1186/s12879-014-0607-z" ns0:type="simple">10.1186/s12879-014-0607-z</ext-link></comment> <object-id pub-id-type="pmid">25425433</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref029"><label>29</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Goldstein</surname> <given-names>EJ</given-names></name>, <name name-style="western"><surname>Citron</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Merriam</surname> <given-names>CV</given-names></name>, <name name-style="western"><surname>Warren</surname> <given-names>YA</given-names></name>, <name name-style="western"><surname>Tyrrell</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Fernandez</surname> <given-names>HT</given-names></name>. <article-title>In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 <italic>Corynebacterium</italic> clinical isolates</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2003</year>;<volume>47</volume>(<issue>1</issue>):<fpage>337</fpage>&#8211;<lpage>41</lpage>. <ext-link ext-link-type="uri" ns0:href="http://www.ncbi.nlm.nih.gov/pubmed/12499210" ns0:type="simple">http://www.ncbi.nlm.nih.gov/pubmed/12499210</ext-link>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/AAC.47.1.337-341.2003" ns0:type="simple">10.1128/AAC.47.1.337-341.2003</ext-link></comment></mixed-citation></ref>
<ref id="pone.0220671.ref030"><label>30</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>O&#8217;Connor</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Galang</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Sambol</surname> <given-names>SP</given-names></name>, <name name-style="western"><surname>Hecht</surname> <given-names>DW</given-names></name>, <name name-style="western"><surname>Vedantam</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Gerding</surname> <given-names>DN</given-names></name>, <etal>et al</etal>. <article-title>Rifampin and rifaximin resistance in clinical isolates of <italic>Clostridium difficile</italic></article-title>. <source>Antimicrob Agents Chemother</source>. <year>2008</year>;<volume>52</volume>(<issue>8</issue>):<fpage>2813</fpage>&#8211;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/AAC.00342-08" ns0:type="simple">10.1128/AAC.00342-08</ext-link></comment> <object-id pub-id-type="pmid">18559647</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref031"><label>31</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Chang</surname> <given-names>LL</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>HF</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>CY</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>WJ</given-names></name>. <article-title>Contribution of integrons, and SmeABC and SmeDEF efflux pumps to multidrug resistance in clinical isolates of <italic>Stenotrophomonas maltophilia</italic></article-title>. <source>J Antimicrob Chemother</source>. <year>2004</year>;<volume>53</volume>(<issue>3</issue>):<fpage>518</fpage>&#8211;<lpage>21</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1093/jac/dkh094" ns0:type="simple">10.1093/jac/dkh094</ext-link></comment> <object-id pub-id-type="pmid">14749340</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref032"><label>32</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Pickering</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Wilcox</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Chilton</surname> <given-names>CH</given-names></name>. <article-title>Biofilm-derived spores of <italic>Clostridioides</italic> (<italic>Clostridium</italic>) difficile exhibit increased thermotolerance compared to planktonic spores</article-title>. <source>Anaerobe</source>. <year>2018</year>;<volume>54</volume>:<fpage>169</fpage>&#8211;<lpage>71</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.anaerobe.2018.10.003" ns0:type="simple">10.1016/j.anaerobe.2018.10.003</ext-link></comment> <object-id pub-id-type="pmid">30292821</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref033"><label>33</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Lawley</surname> <given-names>TD</given-names></name>, <name name-style="western"><surname>Croucher</surname> <given-names>NJ</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Clare</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sebaihia</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Goulding</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Proteomic and genomic characterization of highly infectious <italic>Clostridium difficile</italic> 630 spores</article-title>. <source>J Bacteriol</source>. <year>2009</year>;<volume>191</volume>(<issue>17</issue>):<fpage>5377</fpage>&#8211;<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/JB.00597-09" ns0:type="simple">10.1128/JB.00597-09</ext-link></comment> <object-id pub-id-type="pmid">19542279</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref034"><label>34</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Marin</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Martin</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Alcala</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Cercenado</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Iglesias</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Reigadas</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title><italic>Clostridium difficile</italic> isolates with high linezolid MICs harbor the multiresistance gene cfr</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2015</year>;<volume>59</volume>(<issue>1</issue>):<fpage>586</fpage>&#8211;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/AAC.04082-14" ns0:type="simple">10.1128/AAC.04082-14</ext-link></comment> <object-id pub-id-type="pmid">25385106</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref035"><label>35</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Berger</surname> <given-names>FK</given-names></name>, <name name-style="western"><surname>Rasheed</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Araj</surname> <given-names>GF</given-names></name>, <name name-style="western"><surname>Mahfouz</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Rimmani</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Karaoui</surname> <given-names>WR</given-names></name>, <etal>et al</etal>. <article-title>Molecular characterization, toxin detection and resistance testing of human clinical <italic>Clostridium difficile</italic> isolates from Lebanon</article-title>. <source>Int J Med Microbiol</source>. <year>2018</year>;<volume>308</volume>(<issue>3</issue>):<fpage>358</fpage>&#8211;<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.ijmm.2018.01.004" ns0:type="simple">10.1016/j.ijmm.2018.01.004</ext-link></comment> <object-id pub-id-type="pmid">29478838</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref036"><label>36</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Freeman</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Vernon</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Morris</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Nicholson</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Todhunter</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Longshaw</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Pan-European longitudinal surveillance of antibiotic resistance among prevalent <italic>Clostridium difficile</italic> ribotypes</article-title>. <source>Clin Microbiol Infect</source>. <year>2015</year>;<volume>21</volume>(<issue>3</issue>):<fpage>248 e9</fpage>&#8211;<lpage>e16</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.cmi.2014.09.017" ns0:type="simple">10.1016/j.cmi.2014.09.017</ext-link></comment> <object-id pub-id-type="pmid">25701178</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref037"><label>37</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Camacho-Ortiz</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Lopez-Barrera</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Hernandez-Garcia</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Galvan-De Los Santos</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Flores-Trevino</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Llaca-Diaz</surname> <given-names>JM</given-names></name>, <etal>et al</etal>. <article-title>First report of <italic>Clostridium difficile</italic> NAP1/027 in a Mexican hospital</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>4</issue>):<fpage>e0122627</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1371/journal.pone.0122627" ns0:type="simple">10.1371/journal.pone.0122627</ext-link></comment> <object-id pub-id-type="pmid">25915544</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref038"><label>38</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Lawley</surname> <given-names>TD</given-names></name>, <name name-style="western"><surname>Clare</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Walker</surname> <given-names>AW</given-names></name>, <name name-style="western"><surname>Goulding</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Stabler</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Croucher</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Antibiotic treatment of <italic>Clostridium difficile</italic> carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts</article-title>. <source>Infect Immun</source>. <year>2009</year>;<volume>77</volume>(<issue>9</issue>):<fpage>3661</fpage>&#8211;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/IAI.00558-09" ns0:type="simple">10.1128/IAI.00558-09</ext-link></comment> <object-id pub-id-type="pmid">19564382</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref039"><label>39</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Mathur</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Rea</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Cotter</surname> <given-names>PD</given-names></name>, <name name-style="western"><surname>Hill</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Ross</surname> <given-names>RP</given-names></name>. <article-title>The efficacy of thuricin CD, tigecycline, vancomycin, teicoplanin, rifampicin and nitazoxanide, independently and in paired combinations against <italic>Clostridium difficile</italic> biofilms and planktonic cells</article-title>. <source>Gut Pathog</source>. <year>2016</year>;<volume>8</volume>:<fpage>20</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1186/s13099-016-0102-8" ns0:type="simple">10.1186/s13099-016-0102-8</ext-link></comment> <object-id pub-id-type="pmid">27257437</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref040"><label>40</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>James</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Chesnel</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Boegli</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>deLancey Pulcini</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Fisher</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Stewart</surname> <given-names>PS</given-names></name>. <article-title>Analysis of <italic>Clostridium difficile</italic> biofilms: imaging and antimicrobial treatment</article-title>. <source>J Antimicrob Chemother</source>. <year>2018</year>;<volume>73</volume>(<issue>1</issue>):<fpage>102</fpage>&#8211;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1093/jac/dkx353" ns0:type="simple">10.1093/jac/dkx353</ext-link></comment> <object-id pub-id-type="pmid">29029221</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref041"><label>41</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Pelaez</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Alcala</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Alonso</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Martin-Lopez</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Garcia-Arias</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Marin</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>In vitro activity of ramoplanin against <italic>Clostridium difficile</italic>, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2005</year>;<volume>49</volume>(<issue>3</issue>):<fpage>1157</fpage>&#8211;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/AAC.49.3.1157-1159.2005" ns0:type="simple">10.1128/AAC.49.3.1157-1159.2005</ext-link></comment> <object-id pub-id-type="pmid">15728918</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref042"><label>42</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Abou Chakra</surname> <given-names>CN</given-names></name>, <name name-style="western"><surname>Pepin</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Sirard</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Valiquette</surname> <given-names>L</given-names></name>. <article-title>Risk factors for recurrence, complications and mortality in <italic>Clostridium difficile</italic> infection: a systematic review</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>6</issue>):<fpage>e98400</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1371/journal.pone.0098400" ns0:type="simple">10.1371/journal.pone.0098400</ext-link></comment> <object-id pub-id-type="pmid">24897375</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref043"><label>43</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Deneve</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Delomenie</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Barc</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Collignon</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Janoir</surname> <given-names>C</given-names></name>. <article-title>Antibiotics involved in <italic>Clostridium difficile</italic>-associated disease increase colonization factor gene expression</article-title>. <source>J Med Microbiol</source>. <year>2008</year>;<volume>57</volume>(<issue>Pt 6</issue>):<fpage>732</fpage>&#8211;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1099/jmm.0.47676-0" ns0:type="simple">10.1099/jmm.0.47676-0</ext-link></comment> <object-id pub-id-type="pmid">18480330</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref044"><label>44</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Edwards</surname> <given-names>AN</given-names></name>, <name name-style="western"><surname>Nawrocki</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>McBride</surname> <given-names>SM</given-names></name>. <article-title>Conserved oligopeptide permeases modulate sporulation initiation in <italic>Clostridium difficile</italic></article-title>. <source>Infect Immun</source>. <year>2014</year>;<volume>82</volume>(<issue>10</issue>):<fpage>4276</fpage>&#8211;<lpage>91</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/IAI.02323-14" ns0:type="simple">10.1128/IAI.02323-14</ext-link></comment> <object-id pub-id-type="pmid">25069979</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref045"><label>45</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Karlsson</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Burman</surname> <given-names>LG</given-names></name>, <name name-style="western"><surname>Akerlund</surname> <given-names>T</given-names></name>. <article-title>Induction of toxins in <italic>Clostridium difficile</italic> is associated with dramatic changes of its metabolism</article-title>. <source>Microbiology</source>. <year>2008</year>;<volume>154</volume>(<issue>Pt 11</issue>):<fpage>3430</fpage>&#8211;<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1099/mic.0.2008/019778-0" ns0:type="simple">10.1099/mic.0.2008/019778-0</ext-link></comment> <object-id pub-id-type="pmid">18957596</object-id></mixed-citation></ref>
<ref id="pone.0220671.ref046"><label>46</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Yun</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Oh</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Griffiths</surname> <given-names>MW</given-names></name>. <article-title><italic>Lactobacillus acidophilus</italic> modulates the virulence of <italic>Clostridium difficile</italic></article-title>. <source>J Dairy Sci</source>. <year>2014</year>;<volume>97</volume>(<issue>8</issue>):<fpage>4745</fpage>&#8211;<lpage>58</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.3168/jds.2014-7921" ns0:type="simple">10.3168/jds.2014-7921</ext-link></comment> <object-id pub-id-type="pmid">24856984</object-id></mixed-citation></ref>
</ref-list>
</back>
<sub-article article-type="aggregated-review-documents" id="pone.0220671.r001" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0220671.r001</article-id>
<title-group>
<article-title>Decision Letter 0</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Chang</surname>
<given-names>Yung-Fu</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Yung-Fu Chang</copyright-holder>
<license ns0:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" ns0:href="http://creativecommons.org/licenses/by/4.0/" ns0:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0220671" document-id-type="doi" document-type="article" id="rel-obj001" link-type="peer-reviewed-article" />
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>0</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">2 Jul 2019</named-content>
</p>
<p>PONE-D-19-15391</p>
<p>High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates</p>
<p>PLOS ONE</p>
<p>Dear Dr. Garza-Gonz&#225;lez,</p>
<p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#8217;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
<p>Your manuscript has been reviewed by an expert in your field. Based on the reviewer's comments, a major revision is needed. I hope that the reviewer's comments are useful to you.</p>
<p>We would appreciate receiving your revised manuscript by 4 weeks. When you are ready to submit your revision, log on to <ext-link ext-link-type="uri" ns0:href="https://www.editorialmanager.com/pone/" ns0:type="simple">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
<p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.</p>
<p>To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" ns0:href="http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ns0:type="simple">http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link></p>
<p>Please include the following items when submitting your revised manuscript:</p>
<p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.</p></list-item></list></p>
<p>Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.</p>
<p>We look forward to receiving your revised manuscript.</p>
<p>Kind regards,</p>
<p>Yung-Fu Chang</p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
<p><bold>Journal Requirements:</bold></p>
<p>1. When submitting your revision, we need you to address these additional requirements.</p>
<p>Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p>
<p><ext-link ext-link-type="uri" ns0:href="http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ns0:type="simple">http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and <ext-link ext-link-type="uri" ns0:href="http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ns0:type="simple">http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link></p>
<p>2. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.</p>
<p><bold>Comments to the Author</bold></p>
<p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
<p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p>2. Has the statistical analysis been performed appropriately and rigorously? </p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p>
<p>The <ext-link ext-link-type="uri" ns0:href="http://www.plosone.org/static/policies.action#sharing" ns0:type="simple">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
<p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p>5. Review Comments to the Author</p>
<p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
<p>Reviewer #1: Authors compared C diff isolates from patients with NR-CDI (non-recurrent CDI) and R-CDI (recurrent CDI) in sporulation, resistance to vancomycin and linezolid, biofilm formation in the presence or absence of other bacteria, biofilm resistance to vancomycin and linezolid, and transcription of factors related in sporulation, biofilm formation, adhesion (spo0A, sigH, slpA, cwp84, agrD1 and luxS). They found that R-CDI isolates had hogher sporulation rates, were more resistant to antibiotics, had higher transcription of sigH, spo0A, agrD1, and Cwp84. The results are interesting to understand to R-CDI and NR-CDI. Howerer, there are issues need to be addressed:</p>
<p>1) line 300: minumum inhibitory concentraion of the biofilm was determined in C didd bioflm model or mocrobiota-Cdiff biofim model?</p>
<p>2) It would be more informative to check transcription of toxins, germination of spores, and adhesionand biofilm formation capability.</p>
<p>**********</p>
<p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" ns0:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ns0:type="simple">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
<p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p>
<p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" ns0:href="https://www.plos.org/privacy-policy" ns0:type="simple">Privacy Policy</ext-link>.</p>
<p>Reviewer #1: No</p>
<p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]</p>
<p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" ns0:href="https://pacev2.apexcovantage.com/" ns0:type="simple">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <email ns0:type="simple">figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
</body>
</sub-article>
<sub-article article-type="author-comment" id="pone.0220671.r002">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0220671.r002</article-id>
<title-group>
<article-title>Author response to Decision Letter 0</article-title>
</title-group>
<related-object document-id="10.1371/journal.pone.0220671" document-id-type="doi" document-type="peer-reviewed-article" id="rel-obj002" link-type="rebutted-decision-letter" object-id="10.1371/journal.pone.0220671.r001" object-id-type="doi" object-type="decision-letter" />
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>1</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="author-response-date">3 Jul 2019</named-content>
</p>
<p>1) line 300: minimum inhibitory concentration of the biofilm was determined in C diff bioflm model or mocrobiota-Cdiff biofim model?</p>
<p>Response: The minimum inhibitory concentrations were determined from C. difficile biofilm without microbiota. The point was clarified in the new manuscript in line 301.</p>
<p>2) It would be more informative to check transcription of toxins, germination of spores, and adhesion and biofilm formation capability.</p>
<p>Response: Regarding the adhesion and biofilm formation, we calculated the adherence capability as adherence index for each isolate producing biofilm, and there was no difference between R-CDI and NR-CDI. This information is included in the manuscript. </p>
<p>We added transcription of toxins as perspectives of the study (line 336). However, we expect a low impact because toxin transcription has shown to be ribotype-dependent and our population was mostly infected with 027 ribotype in either R-CDI or NR-CDI isolates.</p>
<p>We also added germination of spores as perspective (line 330) because our data support the role of sporulation pathway genes (sigH, spo0A), in the development of recurrent CDI.</p>
<supplementary-material id="pone.0220671.s001" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" ns0:href="info:doi/10.1371/journal.pone.0220671.s001" ns0:type="simple">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers.doc</named-content></p>
</caption>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="aggregated-review-documents" id="pone.0220671.r003" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0220671.r003</article-id>
<title-group>
<article-title>Decision Letter 1</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Chang</surname>
<given-names>Yung-Fu</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Yung-Fu Chang</copyright-holder>
<license ns0:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" ns0:href="http://creativecommons.org/licenses/by/4.0/" ns0:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0220671" document-id-type="doi" document-type="article" id="rel-obj003" link-type="peer-reviewed-article" />
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>1</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">22 Jul 2019</named-content>
</p>
<p>High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates.</p>
<p>PONE-D-19-15391R1</p>
<p>Dear Dr. Garza-Gonz&#225;lez,</p>
<p>We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.</p>
<p>Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.</p>
<p>Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <ext-link ext-link-type="uri" ns0:href="https://www.editorialmanager.com/pone/" ns0:type="simple">https://www.editorialmanager.com/pone/</ext-link>, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <email ns0:type="simple">authorbilling@plos.org</email>.</p>
<p>If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email ns0:type="simple">onepress@plos.org</email>.</p>
<p>With kind regards,</p>
<p>Yung-Fu Chang</p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
<p>Additional Editor Comments (optional):</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p><bold>Comments to the Author</bold></p>
<p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#8220;Comments to the Author&#8221; section, enter your conflict of interest statement in the &#8220;Confidential to Editor&#8221; section, and submit your "Accept" recommendation.</p>
<p>Reviewer #1: All comments have been addressed</p>
<p>**********</p>
<p>2. Is the manuscript technically sound, and do the data support the conclusions?</p>
<p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p>3. Has the statistical analysis been performed appropriately and rigorously? </p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p>4. Have the authors made all data underlying the findings in their manuscript fully available?</p>
<p>The <ext-link ext-link-type="uri" ns0:href="http://www.plosone.org/static/policies.action#sharing" ns0:type="simple">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p>5. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
<p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
<p>Reviewer #1: Yes</p>
<p>**********</p>
<p>6. Review Comments to the Author</p>
<p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
<p>Reviewer #1: all comments have been addressed. The manuscript is technically sound, with appropriate statistics. Well written with clarity and simplicity.</p>
<p>**********</p>
<p>7. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" ns0:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ns0:type="simple">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
<p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p>
<p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" ns0:href="https://www.plos.org/privacy-policy" ns0:type="simple">Privacy Policy</ext-link>.</p>
<p>Reviewer #1: No</p>
</body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0220671.r004" specific-use="acceptance-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0220671.r004</article-id>
<title-group>
<article-title>Acceptance letter</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Chang</surname>
<given-names>Yung-Fu</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Yung-Fu Chang</copyright-holder>
<license ns0:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" ns0:href="http://creativecommons.org/licenses/by/4.0/" ns0:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0220671" document-id-type="doi" document-type="article" id="rel-obj004" link-type="peer-reviewed-article" />
</front-stub>
<body>
<p>
<named-content content-type="letter-date">23 Jul 2019</named-content>
</p>
<p>PONE-D-19-15391R1 </p>
<p>High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent <italic>Clostridium</italic> [<italic>Clostridioides</italic>] <italic>difficile</italic> infection isolates. </p>
<p>Dear Dr. Garza-Gonz&#225;lez:</p>
<p>I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
<p>If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email ns0:type="simple">onepress@plos.org</email>.</p>
<p>For any other questions or concerns, please email <email ns0:type="simple">plosone@plos.org</email>. </p>
<p>Thank you for submitting your work to PLOS ONE.</p>
<p>With kind regards,</p>
<p>PLOS ONE Editorial Office Staff</p>
<p>on behalf of</p>
<p>Dr. Yung-Fu Chang  </p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
</body>
</sub-article>
</article>